| Back to Press Releases Trinity Biotech Commences Sales of Five Newly FDA-Approved Products Dublin, Ireland, June 4, 1997 Trinity Biotech plc (NASDAQ:TRIBY) today announced that it has begun shipping five new products that have recently received marketing approval from the U.S. Food and Drug Administration. These products, Lyme IgG, Lyme IgG/IgM, Legionella, Chlamydia IgG and Herpes Group Antigen, are all in the micro-titre Enzyme Immunoassay ("EIA") format. The products are being shipped to Wampole Laboratories, a division of Carter-Wallace, Inc. (NYSE:CAR), with which Trinity has an exclusive supply agreement for micro-titre based EIA tests in the U.S. The products are manufactured in Trinity's Jamestown, NY facility, which has both ISO 9001 and FDA registration. Commenting on today's announcement, Ronan O'Caoimh, CEO of Trinity, said, "We are delighted to commence sales of these FDA-approved tests manufactured by Trinity for Wampole under our exclusive supply agreement. We remain committed to the continued expansion of our infectious disease product line, with further FDA submissions planned for the remainder of 1997 for both Trinity's rapid and EIA tests. The combined market potential for these five new tests is very significant, with, for example, more than 4 million new chlamydia infections in the U.S. each year." Trinity Biotech develops, manufactures and markets diagnostic tests for the point-of-care, over-the counter and clinical laboratory markets. For further information: Jonathan O'Connell, Trinity Biotech 800 603 8076 Robert Long, LongView Partners 212 463 9733 |